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Abstract
Background: Maternal immunisation to boost respiratory syncytial virus (RSV) specific antibodies in pregnant
women is a strategy to enhance infant protection. The timing of maternal vaccination during pregnancy may be
critical for its effectiveness. However, Kenya has no documented published data on gestational age distribution of
pregnant women attending antenatal care (ANC), or the proportion of women attending ANC during the proposed
window period for vaccination, to inform appropriate timing for delivery or estimate potential uptake of this
vaccine.
Methods: A cross-sectional survey was conducted within the Kilifi Health and Demographic Surveillance System
(KHDSS), coastal Kenya. A simple random sample of 1000 women who had registered pregnant in 2017 to 2018
and with a birth outcome by the time of data collection was taken. The selected women were followed at their
homes, and individually written informed consent was obtained. Records of their antenatal attendance during
pregnancy were abstracted from their ANC booklet. The proportion of all pregnant women from KHDSS (55%) who
attended for one or more ANC in 2018 was used to estimate vaccine coverage.
Results: Of the 1000 women selected, 935 were traced with 607/935 (64.9%) available for interview, among whom
470/607 (77.4%) had antenatal care booklets. The median maternal age during pregnancy was 28.6 years. The
median (interquartile range) gestational age in weeks at the first to fifth ANC attendance was 26 (21–28), 29 (26–
32), 32 (28–34), 34 (32–36) and 36 (34–38), respectively. The proportion of women attending for ANC during a
gestational age window for vaccination of 28–32 weeks (recommended), 26–33 weeks and 24–36 weeks was 76.6%
(360/470), 84.5% (397/470) and 96.2% (452/470), respectively. Estimated vaccine coverage was 42.1, 46.5 and 52.9%
within the narrow, wide and wider gestational age windows, respectively.
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Conclusions: In a random sample of pregnant women from Kilifi HDSS, Coastal Kenya with card-confirmed ANC
clinic attendance, 76.6% would be reached for maternal RSV vaccination within the gestational age window of 28–
32 weeks. Widening the vaccination window (26–33 weeks) or (24–36 weeks) would not dramatically increase
vaccine coverage and would require consideration of antibody kinetics data that could affect vaccine efficacy.
Keywords: Pregnant women, Antenatal care attendance, Gestational age, Maternal respiratory syncytial virus
vaccine, Effectiveness
Background
Respiratory syncytial virus (RSV) is the main cause of se-
vere lower respiratory tract infections among infants 0–
5 months of age [1, 2]. Globally, RSV is estimated to
have caused 1·4 million hospital admissions for acute
lower respiratory infections and 27,300 in-hospital
deaths of infants under 6 months of age in 2015, with
96% of these occurring in developing countries [3]. Ana-
lysis from a multi-site etiology study conducted in
2011–2014 in sub-Saharan Africa and Asia, revealed that
nearly 40% of all hospital admissions with severe or very
severe pneumonia among infants under 1 year, were
caused by RSV [1].
With the highest burden of RSV disease in early in-
fancy, particularly in those under 3 months of life [4], a
vaccine to administer in the first few weeks of life would
appear to be the most logical target for RSV disease pre-
vention. However, development of such a vaccine has
faced major difficulties such as poor immunological re-
sponses and reactogenicity to vaccines in this age group
[5–7]. Thus to date there are no licenced childhood vac-
cines for RSV. A preventive strategy which involves pro-
viding prophylaxis to infants at birth and during RSV
season is in advanced stages of clinical trials
(NCT03959488). Trials which intramuscularly adminis-
tered a long acting RSV Prefusion F-targeting monoclo-
nal antibody (MEDI8897) in healthy preterm infants
showed the monoclonal antibody to be safe and protect-
ive against medically attended RSV [8, 9].
Maternal vaccination is currently considered the most
plausible strategy for the near term to protect these infants
[10–12]. Several candidate maternal RSV vaccines are ad-
vancing in phase 2 and phase 3 clinical trials [13, 14]. A
RSV F subunit protein vaccine design is progressing to-
wards late stage trials (NCT04032093). A maternal RSV
vaccine candidate of nanoparticle design (NCT02624947)
completed phase 3 of clinical trials in early 2019. Accord-
ing to results of the phase 3 trial, the vaccine prevented
RSV associated disease hospitalization in young infants 3
months of age, by 44.4% (95% CI; 19.6–61.5%). The trial
results also showed that mothers immunized < 33 weeks
of gestational age had higher vaccine efficacy across all
endpoints [15, 16]. In a study for maternal Tetanus-
Diphtheria-acellular pertussis vaccine, anti-pertussis IgG
avidity was found to be higher when the vaccine was ad-
ministered during 28–32 weeks gestation [17].
Following progress in development of maternal RSV
vaccines, it is considered that these vaccines will be par-
ticularly beneficial in low income countries due to the
disproportionate RSV disease burden. A gap analysis re-
port (https://www.path.org/resources/roadmap-advan-
cing-rsv-maternal-immunization/) on advancing
maternal immunization, proposes introduction of mater-
nal RSV vaccines in low- and middle-income countries
(LMICs) through the ANC platform. However, maternal
characteristics including ANC attendance patterns
among women in LMICs are different from those in
high income countries where efficacy trials are con-
ducted. The level of RSV specific antibodies rapidly
wanes over time [18] and decline to pre-infection levels
within 3 months [19]. Therefore, timing of a maternal
RSV vaccine delivery should be within a window of ges-
tational age that will result in maximum benefit to the
infant. Accurate gestational age information from preg-
nant women attending for ANC screening in LMICs is
required to inform the timing of vaccine delivery and ex-
pected vaccine coverage. Data on multiple ANC visits is
lacking in sub-Saharan Africa countries, since the Na-
tional Demographic Health Surveys (DHS) focus on col-
lecting data from the first ANC visit only [20].
In this study, we aim to describe the distribution of
gestational age at each attendance for ANC care among
pregnant women from the population of the Kilifi Health
and Demographic Surveillance System (KHDSS) area,
Coastal Kenya. We also describe the proportions attend-
ing ANC during a proposed vaccination window, we es-
timate the maternal RSV vaccine coverage and how this
may influence the successful implementation of a mater-
nal RSV vaccine program in this setting.
Methods
Study population
The study was conducted in Kilifi County, coastal Kenya
at the KEMRI Wellcome Trust Research Programme
(KWTRP). Collection of gestational age data was carried
out within the KHDSS area. The KHDSS, described else-
where in detail [21, 22], was established in 2000 by
KWTRP for the purposes of demographic surveillance
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and epidemiological research. The area under surveillance
comprises, administratively, 15 locations and 40 sub-
locations, covering an area of 890km2, extending 35 km
north and south of Kilifi County Hospital (KCH) in Kilifi
town [22]. Currently, the system monitors a population of
around 300,000 residents through enumeration rounds
conducted three times a year. The number of pregnancies
occurring per year is registered during these enumeration
rounds. The crude birth rate is approximately 8000 live
births per year [22]. A survey asking all pregnant women in
the KHDSS, if they attended ANC was introduced into the
pregnancy monitoring questionnaire in 2018.
KHDSS census registers were used to select a random
sample of women to participate in this study. A standard
method [23] was used to determine the sample size by
which to estimate the proportion of women attending each
ANC visit with a precision of +/− 5%. A sample size of 384
women was determined using an assumption that the ges-
tational age of each of the recommended four ANC individ-
ual visits by pregnant women from Kilifi HDSS population
would be representative of the general population of preg-
nant women in coastal Kenya. This relates to the median
gestational age at first ANC visit obtained from the 2014
Kenya Demographic Health Survey of 24 weeks [20].
To overcome limitations of missing data due to missed
ANC visits and unavailable ANC booklets from KHDSS
women residents, initially estimated at 60% (unpublished
data from KHDSS pregnancy monitoring survey), a total
of 1000 women were randomly selected from the census
register within the KWTRP integrated database. The
study included women with a pregnancy registered in
2017 and 2018 census rounds and who had a birth out-
come by the time of data collection (October 2018 to
February 2019). These women were traced and visited at
their homes by trained fieldworkers. Informed consent
was sought and if a woman was willing to participate,
she was requested to present her ANC booklet. Records
on gestational age at attendance for ANC care, tetanus
vaccine uptake, birth outcomes and other demographic
details were extracted from the ANC booklets. Gesta-
tional age in the ANC booklets was estimated by fundal
height. Additional information on socio-cultural factors
and other obstetric history was collected using a stan-
dardized electronic questionnaire (Additional file 1)
loaded in computer tablets. For women not found at
home during the first visit, two more follow-ups were
made and further attempt to locate them through other
household members were conducted, after which they
were confirmed to be not available for interview.
Ethical considerations
Informed consent was obtained in writing from all par-
ticipants. This study was approved by the KEMRI Scien-
tific and Ethical Review Unit Committee (SERU #3716).
Statistical analyses
Data were analysed in STATA version 13.1 (College Sta-
tion, Texas). Gestational age dating in weeks was mea-
sured by fundal height which is standard practice in all
public health facilities in Kenya. Trimester was defined as
1 (1–12 weeks), trimester 2 (13–26 weeks) and trimester 3
(27–42 weeks). A further three gestational age categories
were generated by which to assess ANC initiation, i.e. <
16 weeks, early initiation as recommended by Kenya na-
tional guidelines for quality obstetric care [24], 16–28
weeks: mid initiation (timing of second visit), 29–42 week:
late initiation which corresponds with timing of third and
fourth ANC visits. Gestational ages in weeks at ANC visits
were presented as mean (Standard Deviation; (SD)), me-
dian and interquartile range (IQR). Proportions of women
attending ANC during three potential gestational age win-
dows for vaccine delivery (i.e. 28–32 weeks, 26–33 weeks
and 24–36 weeks) were calculated. For each of the three
defined vaccination windows, namely gestational age of
pregnancy ranging from 28 to 32 weeks or 26 to 33 weeks
or 24 to 36, the number of women attending ANC was
computed and presented as a proportion of all women
with ANC attendance records. Vaccine coverage was esti-
mated as a product of the proportion of women attending
ANC during a potential gestational age window for mater-
nal RSV vaccine delivery and the proportion of all women
from the KHDSS with birth outcomes registered in 2018
and who reported to have attended ANC. A chi-square
test was performed to assess the association between ges-
tational age at first ANC attendance and maternal charac-
teristics. The characteristics of women within the KHDSS
area with and without ANC booklets were compared
using the chi-square test. Density curves for the distribu-
tion of gestational age at ANC attendance were generated.
Results
Of the 1000 women selected from the KHDSS database,
935 were visited at their home of whom 607/935 (64.9%)
were available for interview. Of those available, 594/607
(97.9%) consented to enroll into the study. Overall, 470/
607 (77.4%) reported their ANC booklet was available,
119/607 (19.6%) reported it was lost and 5/607 (0.8%)
said it was not issued (Fig. 1). The median (interquartile,
IQR) age at the time of pregnancy was 28.6 years (23.4–
33.6). The youngest was 14.5 years while the oldest was
48.3 years. About a third of these women, 228 (38.4%),
were either in their first or second pregnancy. The high-
est parity was 13 pregnancies.
Characteristics of pregnant women with and without ANC
booklets
There were no significant differences between pregnant
women with (n = 470) and without (n = 124) ANC book-
lets in the following demographic characteristics:
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maternal age (χ2, P = 0.431), education level (χ2, P =
0.238), occupation (χ2, P = 0.266), marital status (χ2, P =
0.288), religion (χ2, P = 0.081) and number of pregnan-
cies (χ2, P = 0.189). Significant difference was identified
for place of delivery (χ2, P = 0.015). Women without
ANC booklets were more likely to have delivered at
home (38.7% vs 27.5%) (Table 1).
Distribution of gestational age at ANC visits among
pregnant women in Kilifi
The distribution of how pregnant women in Kilifi
attended for ANC screening is shown using density
curves in Fig. 2 and Fig. 3. Gestational age at first ANC
visit varied widely and progressively diminished with in-
creasing ANC visit number (Fig. 3). Some women
attended for first ANC care at less than 10 weeks of ges-
tation while others visited in their 40th week of
pregnancy.
The median gestational age among women at attend-
ance for first to fifth ANC visit was 26 weeks (IQR: 21–
28), 29 weeks (26–32), 32 weeks (28–35), 34 weeks (32–
36) and 36 weeks (34–38), respectively (Fig. 4).
The mean (SD) gestational age in which women
attended for their first to fifth ANC care was 24.5 (7.2)
weeks, 28.9 (5.0) weeks, 31.6 (4.2) weeks, 34.3 (3.2)
weeks and 35.9 (2.8) weeks, respectively (Table 2).
The proportion of women attending for first to fifth
ANC visit is shown in Fig. 4. A total of 83.6% (393/470)
attended second ANC, 60.9% (286/470) third ANC,
34.5% (162/470) fourth ANC and 9.8% (46/470) attended
a fifth ANC visit. (Fig. 4).
The median gestational age at first ANC visit among
women who attended one, two, three, four or five visits
was 30 weeks (IQR: 26–34), 28 weeks (26–31), 24 weeks
(22–28), 23 weeks (20–26) and 18 weeks (12–20), re-
spectively (Table 3).
The proportion of women who attended one, two,
three, four or five ANC visits was 16.4% (77/470), 22.8%
(107/470), 26.4%(124/470), 24.7%(116/470) and 9.8%(46/
470), respectively.
The proportion of all pregnant women from the
KHDSS with birth outcomes registered in 2018 who re-
ported to have attended at least one ANC was 55%. This
proportion was obtained from pregnancy monitoring
data collected during enumeration rounds.
Proportion of women attending ANC within a specific
gestational age window for maternal RSV vaccine delivery
The proportion of pregnant women participants with
ANC booklets, who attended for ANC during the nar-
row (28–32 weeks gestation period) and wide (26–33
weeks) or wider (24–36 weeks gestation period), was
76.6% (360/470), 84.5% (397/470) and 96.2% (452/470),
respectively, Table 2. Of the women attending an ANC
clinic during weeks 28–32 gestational age, 29.6% were
attending for their first visit, 39.8% for their second,
26.2%, for their third, 10% for their 4th and 1% for their
5th. For the 26–33 weeks gestational age window, close
to half (48.9%) were attending for their second visit. For
the wider vaccination window of 24–36 weeks gestation,
64.7% were in their first ANC visit, 72.3% in their sec-
ond, 52.9% third and 6.6% in their fifth visit (Table 2).
The proportion of pregnant women who attended only
one ANC visit and would have been reached for vaccin-
ation at the gestational age window of 28–32 weeks, 26–
33 weeks and 24–36 weeks was 6.0%(28/470),7.5%(35/
470) and 12.8%(60/470) respectively (Table 3).
Tetanus vaccine coverage during the proposed maternal
RSV vaccination window
Pregnant women received either a single or multiple
doses of tetanus vaccine as they attended for ANC
care. Out of the 470 women with ANC booklets, 18
(3.8%) received a tetanus in their first trimester, 206
(43.8%) in the second trimester and 298 (63.4%) dur-
ing the third trimester (27–42 weeks gestation). A
total of 257 (54.7%) women received tetanus vaccine
within the potential gestational age window period for
maternal RSV vaccination of 28–32 weeks and 284
(60.4%) during the wide window of 26–33 weeks.
Overall, 316/470 (67.2%) of the women received a tet-
anus vaccine (either one or more doses) during ANC
visits.
Fig. 1 Flow chart showing sampling of women from Kilifi Health and
Demographic Surveillance System area who participated in the study
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Factors influencing ANC initiation and uptake of health
services among pregnant women in Kilifi
The proportion of women attending for first ANC visit
while in their first, second or third trimester of preg-
nancy were 4.9% (23/470), 53.8% (253/470) and 41.3%
(194/470) respectively. A very low proportion of the
women (5.9%; 28/470) had an early initiation of first
ANC visit of less than 16 weeks as recommended by the
Kenya national guidelines for quality obstetric care [24].
Delay on initiation of first ANC visit was significantly as-
sociated with being of older maternal age (i.e. 35 years
and above) at the time of pregnancy (χ2, P = 0.022), edu-
cation below secondary level (χ2, P = 0.021) and prefer-
ence for home births (χ2, P < 0.001). We did not find any
significant association between gestational age at first
ANC visit and marital status (χ2, P = 0.798), travel dis-
tance (in kilometres) from home of the participant to
the ANC health facility (χ2, P = 0.436), gravida (χ2, P =
0.078) and religion (χ2, P = 0.477) (Table 4).
When the 594 women were asked about the decision
on timing for ANC screening when pregnant, 564
(94.9%) reported having made their own decision on
when to attend for ANC screening. However, 30 (5%) re-
ported they consulted either spouse or relative. The
great majority of women interviewed (585, 98.5%) re-
ported they attended ANC for the wellbeing of them-
selves and their unborn child. Six (1.0%) reported it was
because of pregnancy complications while the remainder
were following advice from friends and relatives.
Among those who delivered at home (177 women,
29.8%), a total of 58 (32.8%) of the participants reported
that this was due to the distance to the health facility, 47
(26.6%) reported it was as a result of doctors’ and nurses’
strikes, while 71 (40.1%) had other reasons. There was a
strong association between education level and choice of
place for delivery (χ2, P < 0.001). A majority of women
with primary level of education (8 years of formal educa-
tion) or less had their babies delivered at home.
Table 1 Characteristics of women with and without ANC booklets sampled from the Kilifi Health Demographic Surveillance System
(KHDSS) area, Coastal Kenya
Characteristics With booklet n (%) Without booklet n (%) Total
N (%)
Chi2 P value
N 470 (79.1) 124 (20.9) 594 (100)
Age class
15–19 24 (5.1) 5 (4.0) 29 (4.9)
20–24 115 (24.5) 29 (23.4) 144 (24.2)
25–29 110 (23.4) 21 (16.9) 131 (22.1) 0.431
30–34 116 (24.7) 35 (28.2) 151 (25.4)
35–39 66 (14.0) 16 (12.9) 82 (13.8)
40–44 34 (7.23) 15 (12.1) 49 (8.25)
45–49 6 (1.3) 2 (1.6) 8 (1.4)
Marital status
Married 434 (92.3) 111 (89.5) 545 (91.8)
Single 34 (7.2) 11 (8.9) 45 (7.5) 0.288
Divorced/Sep/Widowed 2 (0.4) 2 (1.6) 4 (0.7)
Delivery place
Health facility 341 (72.6) 76 (61.3) 417 (70.2) 0.015
Home 129 (27.5) 48 (38.7) 177 (29.8)
Education level
None 82 (17.5) 17 (13.7) 99 (16.7)
Primary 326 (69.4) 97 (78.2) 423(71.2) 0.238
Secondary 48 (10.2) 7 (5.7) 55(9.3)
Tertiary-College/University 14 (3.0) 3 (2.4) 17 (2.9)
Gravida
1–2 188 (39.8) 40 (32.3) 228 (38.4)
3–5 159 (33.8) 43 (33.8) 201 (33.8) 0.189
6–9 110 (23.4) 39 (31.5) 149 (25.1)
10–15 14 (3.0) 2 (1.6) 16 (2.7)
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Discussion
Maternal immunisation to boost RSV specific antibodies,
is a strategy proposed to protect infants against RSV as-
sociated disease within the first few months of life [15,
25]. Implementation of a maternal RSV vaccine program
will be influenced by several factors, one of them being
the appropriate timing of vaccination. The window of
gestational age at vaccination that will result in optimal
maternal RSV-specific antibody transfer to the infant de-
pends on antibody kinetics. However, a major unknown
is the distribution of gestational age at ANC visits that
determines the proportion of women who attend at the
ideal window for vaccination. Here we provide a detailed
analysis of the gestational age at attendance for ANC
screening, the proportion attending ANC within a spe-
cific gestational age window for vaccine delivery and de-
scribe the related factors among pregnant women in
Kilifi.
A random sample of women was selected from the
registers of a demographic surveillance area. Not all
women had an ANC booklet. Those with or those with-
out ANC booklet did not differ in most characteristics
(e.g. maternal age, occupation, education level, marital
status, religion and number of pregnancies), but did
29.6%
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41.9%
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Fig. 3 Density distribution curves of gestational age in weeks at initiation of first ANC visit by number of ANC visits attended among women
sampled from the KHDSS area. Each curve represents participant’s number of ANC visits i.e. one visit to five visits. Three gestational age windows
(28–32 weeks), (26–33 weeks) and (24–36 weeks) for maternal RSV vaccination and the proportion of women attending within that gestational
age window during the first ANC visit (29.6, 41.9 and 64.7% respectively), are also shown
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Fig. 2 Density distribution curves of gestational age by ANC visit among women sampled from the KHDSS area. Each curve represents
participant’s ANC visits i.e. visit one to fifth. The three gestational age windows (28–32 weeks), (26–33 weeks) and (24–36 weeks) for maternal RSV
vaccination and the proportion of women attending within that gestational age window (76.6, 84.5 and 96.2% respectively), are also shown
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differ in place of delivery. This was an important obser-
vation to address potential bias in the results that would
have been associated with sampling of the participants
or missing data.
We found initiation of first ANC visit (median 26
weeks) among KHDSS women is later than the WHO
guidelines for a first visit of first 12 weeks’ gestation [26]
and as recommended by the Kenya national guidelines
for quality obstetric care [24]. Although we found the
delay in ANC initiation to be associated with other mul-
tiple factors, late presentation for first ANC screening
limited the number of visits a pregnant woman could at-
tend. Kenya still implements the basic ANC model of
four ANC visits [24] which recommend first visit less
than 16 weeks of gestation, second visit between 16 to
28 weeks, third visit between 28 to 32 weeks, and fourth
visit between 32 to 40 weeks [24]. The WHO recom-
mends pregnant women to have a total of 8 contacts
with a health care provider [26]. In this study, about 10%
of the women with ANC booklets attended five ANC
visits. Nevertheless, even at the 5th ANC visit, at least
1% were still within the proposed gestational age win-
dow for vaccination. Whereas, among the 77 women
who attended only one ANC visit in this study, 40 of
them would have been missed for maternal RSV vaccin-
ation. This emphasizes the need to encourage pregnant
women to attend multiple ANC visits in order to in-
crease the opportunity of receiving all required health
services, including vaccination.
We computed estimates of the proportion of pregnant
women that would be reached for vaccination if delivery
is through ANC clinics. We estimated 76.6% of pregnant
women (with at least one ANC visit) from the KHDSS
area were within the gestational age window period tar-
geted for vaccination of 28–32 weeks. Widening the vac-
cination window to 26–33 weeks and 24–36 weeks could
ANC1
ANC2
ANC3
ANC4
ANC5
Median=26wks
n=470
Median=29wks
n=393 (83.6%)
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Median=34wks
Median=36wks
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Individual ANC visits for pregnant women from KHDSS area
Fig. 4 A box plot showing the gestational age in weeks against ANC visits among participants from the KHDSS area. Each box represents ANC
visit from first to fifth (i.e. ANC1, ANC2, ANC3, ANC4 and ANC5). The median and proportion of women out of the 470 participants with ANC
booklets attending ANC in each visit is also shown
Table 2 Summary of gestational age in weeks by ANC visit and proportion available for vaccination within a specific window
among pregnant women interviewed from Kilifi Health Demographic Surveillance System area, Coastal Kenya
ANC
Visit
Participant’s
n (%)
Mean Gest age
(weeks)
95% Confidence
Interval (CI)
Median
Gest age
(weeks)
IQR
Gest age
(weeks)
Proportion VAC-
Window1
(28–32 weeks
Proportion VAC-
Window2
(26–33 weeks)
Proportion VAC-
Window3
(24–36 weeks)
ANC1 470 (100) 24.5 23.9–25.2 26 21–28 29.6 41.9 64.7
ANC2 393 (83.6) 28.9 28.4–29.4 29 26–32 39.8 48.9 72.3
ANC3 286 (60.8) 31.6 31.1–32.1 32 28–35 26.2 31.9 52.9
ANC4 162 (34.5) 34.3 33.8–34.8 34 32–36 10 12.3 26.4
ANC5 46 (9.8) 36.9 35.0–36.7 36 34–38 1.1 1.3 6.6
Total 470 76.6 84.5 96.2
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see the proportion increase to 84.5 and 96.2%, respect-
ively. The current maternal RSV vaccines in clinical tri-
als are antibody boosting vaccines [13, 14]. Previous
studies have shown that, maternal RSV antibodies from
the KHDSS population decay rapidly at the rate of −
0.58 (SD: 0.20) log2PRNT titre per month [18] and reach
very low levels within a period of three months [19].
The gestational age window for maternal RSV vaccin-
ation is therefore defined to occur within a time when
delivery of the vaccine will ensure there is efficient ma-
ternal antibody transfer, such that the level rising from
boosting and the antibody decay kinetics combine to
provide the infant maximum benefit. A study to assess
effect of timing of Tetanus-Diphtheria-acellular pertussis
vaccine administration in pregnancy showed that vaccin-
ation during 28–32 weeks gestation was associated with
higher anti-pertussis IgG avidity, as compared with vac-
cination during 33–36 weeks gestation [17]. Incorpor-
ation of antibody kinetics data to the wide and wider
potential gestational age windows for maternal RSV vac-
cine delivery will therefore be necessary to confirm vac-
cine efficacy.
We estimated the maternal RSV vaccine coverage in
this population using pregnancy data for ANC attend-
ance collected during enumeration rounds from all
KHDSS pregnant women. This is because we did not
have estimates of pregnant women who reported not to
have attended ANC from the selected sample. A pilot
survey within the KHDSS, asking all women with birth
outcomes if they attended ANC, showed that 55% of the
women who had birth outcomes in 2018 attended for at
least one ANC visit. The KHDSS area records about
8000 pregnancies per year [22]. Assuming 55% of the
8000 KHDSS pregnant women attended ANC and 76.6%
are available for vaccination during the gestational age
window of 28–32 weeks, the vaccine coverage among all
pregnant women within KHDSS area would be 42.1%. A
gestational age window of 26–33 weeks, with 84.5% visit-
ing in the vaccine window, would increase the overall
vaccine coverage to 46.5%. A window of gestational age
of between 24 and 26 weeks with 96.2% of women at-
tending ANC, will have 52.9% vaccine coverage.
In this study, we used maternal tetanus vaccine to as-
sess the proportion of pregnant women that will be
reached for vaccination if there is concomitant adminis-
tration with the maternal RSV vaccine through ANC
platform. We approximated 54.7% of the women in Kilifi
attending ANC who received a tetanus vaccine would be
reached for maternal RSV vaccination within the gesta-
tional age window period of 28–32 weeks. This implies,
the estimated coverage for maternal RSV vaccine will be
30.1% if it is co-administered with tetanus vaccine in this
setting. However, we find these estimates lower than the
maternal tetanus vaccine coverage reported by the min-
istry of health, District Health Information System
(DHIS2) for Kilifi County of 45% for the year 2018. We
note here that, co-administration of multiple vaccines
during ANC attendance is possible though there might
be challenges in obtaining accurate estimates of the vac-
cine coverage. This is likely if one of the vaccines is not
influenced by the gestational age at the time of delivery
and is limited in the number of recommended lifetime
doses one should be eligible for, such as the tetanus
vaccine.
We also found that, factors that influence utilization of
health care services can also influence the level of suc-
cess of a new intervention delivered through health facil-
ities. In this study, we found women who had home
births reported the main reasons as long distance to a
health facility and health-care workers strikes. Notably,
most of these women did not have education beyond
primary school level. A study in Ghana reported socio-
cultural perceived threats to pregnancy forced women to
seek care during pregnancy from multiple sources in-
cluding traditional herbalists [27]. While, a study among
Ethiopian women showed that education status at pri-
mary level was associated with home deliveries [28]. In
our analysis, we did not find travel distance to the health
Table 3 Summary of gestational age in weeks at initiation of first ANC visit by number of visits attended and proportion available
for vaccination within a specific window during the first visit among pregnant women interviewed from Kilifi Health Demographic
Surveillance System area, Coastal Kenya
Number of
ANC Visits
Participants
n (%)
Median
Gest age (weeks) at
First ANC visit
IQR
Gest age (weeks) at
first ANC visit
Proportion VAC-
Window1
(28–32 weeks) at
first ANC visit
Proportion VAC-
Window2
(26–33 weeks) at
first ANC visit
Proportion VAC-
Window3
(24–36 weeks) at
first ANC visit
1 77 (16.4) 30 26–34 6.0 7.5 12.8
2 107 (22.8) 28 26–31 13.6 17.2 21.5
3 124 (26.4) 24 22–28 6.6 10.2 18.1
4 116 (24.7) 23 20–26 3.2 6.8 11.7
5 46 (9.8) 18 12–20 0.2 0.2 0.6
Total 470 (100) 29.6 41.9 64.7
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facility to be related to timing for initiation of ANC visit
(P = 0.436) or choice of a place for delivery. We also do
not think the cost of accessing maternal care might dir-
ectly hinder utilization of health services among Kilifi
women. This is because there are initiatives in Kenya
(“Beyond Zero”) [29] to provide free access to maternal
and child health services for all pregnant women, but
30% of births in this study were reported to have oc-
curred at home. The fact that some women declined to
disclose reasons for not seeking obstetric care during
pregnancy, shows there could be other underlying and
unknown factors that could impact negatively the deliv-
ery of any new maternal vaccine program. Multiple ini-
tiatives as a strategy to encourage and influence positive
health care seeking practices might be useful for this
population. We recommend inclusion of reproductive
health education early in school and further studies that
can engage women who prefer having home deliveries to
understand the key issues restraining them from utiliz-
ing health care services.
There are some limitations to this study. The first and
major limitation is that, pregnancy dating by fundal
Table 4 Characteristics of participants by gestational age at first ANC visit in Kilifi Health Demographic Surveillance System area,
Coastal Kenya
Participants Gestational age at First ANC visit 0–15 weeks 16–28 weeks 29–42 weeks Total n (%) Chi2 P value
Total participants (%) 28 (5.9) 319 (67.9) 128 (26.2) 470 (100)
Age class
15–19 1 (4.2) 19(79.2) 4 (16.7) 24 (5.1)
20–24 5 (4.4) 83(72.2) 27 (23.5) 115 (24.5)
25–29 9 (8.2) 81 (73.6) 20 (18.2) 110 (23.4) 0.022
30–34 4 (3.5) 72 (62.6) 39 (33.9) 115 (24.5)
35–39 6 (9.1) 42 (63.6) 18 (27.3) 66 (11.0)
40–44 1 (2.9) 20 (58.8) 13 (38.2) 34 (7.23)
45–49 2 (33.3) 2 (33.3) 2 (33.3) 6 (1.3)
Gravida
1–2 12 (6.4) 142 (75.5) 34 (18.1) 188 (39.8) 0.078
3–5 9 (5.7) 102 (64.6) 47 (29.8) 158 (33.8)
6–9 6 (5.5) 67 (60.9) 37 (33.6) 110 (23.4)
10–15 1 (7.1) 8 (57.2) 5 (35.7) 14 (3.0)
Distance to ANC health facility (Kms)
0–5 15 (5.2) 198 (68.8) 75 (26.0) 288 (66.5)
6–10 3 (4.0) 52 (69.3) 20 (26.7) 75 (17.8) 0.436
11–20 3 (7.1) 33 (78.6) 6 (14.3) 42 (9.8)
21–30 0 (0) 6 (54.6) 5 (45.4) 11 (2.6)
31–40 1 (11.1) 4 (44.4) 4 (44.4) 9 (2.1)
40–70 1 (16.7) 4 (66.7) 1 (16.7) 6 (1.4)
Education level
None 3 (3.7) 51 (62.2) 28 (34.1) 82 (17.5)
Primary 19 (5.8) 220 (67.5) 87 (26.7) 326 (69.4) 0.021
Secondary 3 (6.2) 37 (77.1) 8 (16.7) 48 (10.2)
Tertiary-College/University 3 (21.4) 11 (78.6) 0 (0) 14 (2.9)
Delivery place
Health facility 25 (7.3) 248 (72.7) 68 (19.9) 341 (72.6) 0.001
Home 3 (2.33) 71 (55.0) 55 (42.6) 129 (27.4)
Marital status
Married 26 (6.0) 296 (68.2) 112 (25.8) 434 (92.4)
Single 2 (5.9) 21 (61.8) 11 (32.3) 34 (7.2) 0.798
Divorced/Sep/Widowed 0 (0) 2 (100.0) 0 (0) 2 (0.4)
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height is not an accurate method for estimating gesta-
tional age. Fundal height is likely to under or overesti-
mate gestational age in this setting. However, this is the
method available and in use in all public hospitals in
Kenya. Pregnancy dating by last menstrual period which
is dependent on participant recall was missing for most
women. Second, only 47% of the random sample of 1000
pregnant women had ANC booklets available. Therefore,
our sample might not be representative of the general
KHDSS pregnant women population. We tried to assess
for this bias using demographic data from our census
registers and we found these women were similar in
most characteristics. Third, women without available
ANC booklets or those who deliver at home may still
have visited ANC clinics and could therefore potentially
receive a vaccine. Fourth, the estimated vaccination win-
dow can only infer vaccine coverage and not necessarily
vaccine effectiveness. Whether within this proposed win-
dow, the infant will have maximum benefit requires in-
corporation of data on antibody kinetics. In addition,
vaccine effectiveness will require assessment of data on
birth weight, gestational age at delivery, prematurity, as
well as health factors like maternal malaria, anaemia,
HIV infection, hypergammaglubinemia etc., which this
study could not address. The present study provides in-
sights into the distribution of gestational age and pro-
portion of pregnant women likely to be reached for
vaccination. Further work is currently ongoing which
will incorporate this data and data on antibody kinetics
from women in this population. This will be used in
mathematical modelling to estimate the optimal gesta-
tional age for maternal RSV vaccine delivery. To our
knowledge, this is the first study from Kenya and sub-
Saharan Africa to present data on timing for ANC visits
which includes gestational age for subsequent visits and
describes how this timing in ANC attendance is likely to
affect the success of a maternal RSV vaccine program.
These data can also be relevant in other maternal vac-
cines such as Group B Streptococcus, Influenza and Per-
tussis in coastal Kenya.
Conclusions
At least 77% of pregnant women from Kilifi HDSS, at-
tending ANC would be reached for maternal RSV vac-
cination delivery through the ANC clinics at the
currently optimum gestational age window. Concomi-
tant administration of tetanus and RSV vaccine in the
same period suggests 55% of women attending ANC
would be available for uptake of both vaccines. Widen-
ing the vaccination window leads to a potential modest
increase in vaccine coverage and its effect requires tak-
ing account of antibody kinetics data. Uncertainty in
these estimates is due to 21% of women having no ANC
card and reaching only 60% of our target population.
Improving ANC attendance is a high priority for the
success of a RSV maternal vaccine. These findings can
be useful in guiding policy development towards imple-
mentation of a maternal RSV vaccine through the ANC
platform in Kenya.
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